FARNBOROUGH, England,
May 20, 2019 /PRNewswire/ --
Flexipharm Austrading the UK specialty pharmaceutical company
focused on supplying the NHS with Better. Critical Care
Medicines, today announced the commercial availability in the
UK of its differentiated arsenic trioxide injection product,
Arsenic Trioxide Phebra, following the successful grant of a
Marketing Authorisation by the MHRA.
Arsenic Trioxide Phebra is a glass vial presentation of arsenic
trioxide 1mg/ml concentrate solution for infusion, a
NICE-recommended treatment (in combination with all-trans
retinoic acid) for newly diagnosed low-intermediate risk and
relapsed acute promyelocytic leukaemia or APML1,2.
Arsenic Trioxide Phebra is the first generic arsenic trioxide
injection product to be launched in the UK and the first in a
preferred vial presentation. The product is supplied by Flexipharm
Austrading's partner, Phebra Pty Ltd, an Australian-based
development and manufacturing company which has a successful track
record in the supply of arsenic trioxide injection
(www.phebra.com).
Commenting on the launch, Michael
Clark, Founder and Director of Flexipharm Austrading,
said: "I am delighted and proud to make Arsenic Trioxide Phebra
available to the NHS. The vial presentation is important as it
removes the very real and common risk of sharps injuries when
opening glass ampoules and saves NHS pharmacist time to make up
infusions as no filter needles or filter straws are needed. We have
also priced this better presentation at 7.7% less than
ampoules3 offering a direct saving to NHS hospitals.
Having a second source of supply for this medicine, which plays a
pivotal role in the successful treatment of APML, is vital for the
NHS."
Flexipharm Austrading will be launching several products in the
UK in 2019 and 2020.
About Flexipharm Austrading
Flexipharm Austrading's vision is to become a UK-based specialty
pharmaceutical company that is genuinely respected and trusted by
NHS hospitals. It was set up in 2018 by Michael Clark, an experienced specialty
pharmaceutical company founder and board director.
Flexipharm Austrading has a singular focus on established
molecules embedded in hospital use where there are concerns around
security of ongoing supply; where the current presentation is not
optimal for the needs of the NHS staff; and where the current
presentations can contribute to medication errors.
Flexipharm Austrading has a deep understanding of the conditions
where its medicines are used and builds enduring meaningful
dialogue with the NHS staff involved in using these medicines. It
has an exclusive distribution agreement with Phebra Pty Ltd, an
Australian pharmaceutical company that develops and manufactures
injectable pharmaceutical products. Flexipharm Austrading will be
launching several products from the Phebra portfolio in the UK in
2019 and 2020.
For further information visit our website,
www.flexipharmaustrading.com.
References
1
https://www.nice.org.uk/guidance/ta526/resources/resource-impact-report-pdf-4850877421
2 https://www.medicines.org.uk/emc/product/10278
3 Ampoule price of £2920.00 for a pack of 10 x
10ml ampoules,
https://bnf.nice.org.uk/medicinal-forms/arsenic-trioxide.html
accessed 17/05/2019. Arsenic Trioxide Phebra NHS price is
£2700.00 for a pack of 10 x 10ml vials
View original
content:http://www.prnewswire.com/news-releases/flexipharm-austrading-announces-launch-of-arsenic-trioxide-phebra-arsenic-trioxide-1mgml-concentrate-for-solution-for-infusion-300853052.html
SOURCE Flexipharm Austrading